Skip to main content
You are using an older version of Internet Explorer that is not supported by MassEyeAndEar.org. Please upgrade for the best experience.

Ashley Miller, M.D.

Miller

Dr. Ashley Miller hails from Cincinnati, Ohio, and attended the University of North Carolina Chapel Hill for her undergraduate degree, where she spent time in the laboratory of Dr. Victoria L. Bautch studying blood vessel development in mice. As an undergraduate, she was also mentored by Dr. Kathryn Wikenheiser-Brokamp of Cincinnati Children’s Hospital/University of Cincinnati Research Foundation as she investigated molecular mechanisms of chemoresistance in small cell lung cancer. 

During medical school, Dr. Miller participated in clinical outcomes research under the guidance of Dr. Michael Englesbe and Dr. Lillian Min. She investigated the relationship between preoperative functional status and postoperative occurrences in older surgical patients. She remains interested in risk assessment and preoperative optimization as it relates to otolaryngology patients.

For more information on Dr. Miller, check out her Harvard Catalyst website.


Education

Undergraduate School
University of North Carolina at Chapel Hill (Biology)

Medical School
University of Michigan Medical School


Publications

p53 suppresses carcinoma progression by inhibiting mTOR pathway activation. Akeno N, Miller AL, Ma X, Wikenheiser-Brokamp KA. Oncogene. 2015 Jan 29;34(5):589-99.

Analytic morphomics corresponds to functional status in older patients. Miller AL, Min LC, Diehl KM, Cron DC, Chan CL, Sheetz KH, Terjimanian MN, Sullivan JA, Palazzolo WC, Wang SC, Hall KE, Englesbe MJ. J Surg Res. 2014 Nov;192(1):19-26.

Variation in ambulatory surgery utilization in Michigan. Sheetz KH, Corona L, Cramm S, Haddad A, Kolar L, Kozminski D, Miller A, Mualla R, Underwood P, Waits SA, Krapohl G, Campbell DA Jr, Englesbe MJ. J Surg Res. 2014 Jun 15;189(2):255-61.

Abstract A18. Conditional mouse models targeting Rb And P53 ablation to the lung and thyroid epithelium develop high grade neuroendocrine carcinomas. Akeno N, Greaves R, Miller AL, Pozniak JP, Wikenheiser-Brokamp KA. Respiratory and Critical Care Medicine: American Thoracic Society International Conference Abstract Issue. 2013 May. 187(1_MeetingAbstracts): A1037-A1037

Abstract 3932: p53 mutation cooperates with Rb loss to promote aggressive metastatic small cell lung cancer in the absence of gain-of-function effects. Akeno N, Greaves R, Miller AL, Wikenheiser-Brokamp KA. Cancer Research. 2014 Oct. 74(19 Supplement): 3932.

Abstract 346: p53 mutation in Rb deficient neuroendocrine lung and thyroid cells results in high grade neuroendocrine carcinomas promoted by mTOR pathway activation. Akeno N, Miller A, Levinsky N, Wikenheiser-Brokamp KA. Cancer Research. 2013 Apr. 73(8 Supplement): 346.